Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen Inc. (OCGN) is a clinical-stage biopharmaceutical company pioneering gene therapies for retinal diseases and innovative vaccine platforms. This dedicated news hub provides investors and researchers with timely updates on Ocugen’s scientific advancements, regulatory milestones, and strategic initiatives.
Access verified press releases and curated financial news covering clinical trial developments, partnership announcements, and corporate updates. Our repository includes updates on modifier gene therapy programs for conditions like retinitis pigmentosa, inhaled vaccine research, and ocular disorder treatments undergoing regulatory review.
Key content categories include progress reports on Phase I-III trials, FDA designations, intellectual property updates, and financial performance summaries. Bookmark this page for streamlined tracking of OCGN’s advancements in gene editing technologies and mucosal vaccine development.
Ocugen (NASDAQ: OCGN) announced an upcoming Clinical Showcase on November 12, 2024, at Nasdaq MarketSite in New York City. The event will highlight progress in their gene therapy clinical trials, including updates on the Phase 3 liMeliGhT trial for retinitis pigmentosa, preliminary data from the Phase 1/2 OCU410 ArMaDa trial for geographic atrophy, and progress on the Phase 1/2 OCU410ST GARDian study for Stargardt disease. The showcase will feature company executives, study investigators, and patient participants. Additionally, information about OCU200, a biologic candidate for diabetic macular edema entering Phase 1 trials, will be presented.
Ocugen, Inc. (NASDAQ: OCGN) announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of the Phase 1/2 clinical trial for OCU410ST, a novel modifier gene therapy candidate for Stargardt disease. The DSMB determined the high dose of OCU410ST to be the maximum tolerated dose, with no serious adverse events reported. The trial will proceed to Phase 2 using high and medium doses.
The first phase enrolled nine patients receiving low, medium, or high doses of OCU410ST via subretinal injection. Dr. Charles Wykoff, a lead study investigator, noted that OCU410ST appears to be safe and well-tolerated. Ocugen's Chief Medical Officer, Dr. Huma Qamar, expressed enthusiasm about OCU410ST's potential to be the first one-time novel modifier gene therapy for Stargardt disease, addressing an unmet medical need for an estimated 100,000 patients in the U.S. and Europe.
Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene and cell therapies, biologics, and vaccines, has announced a conference call and live webcast scheduled for November 8, 2024, at 8:30 a.m. ET. The event will cover the company's third quarter 2024 financial results and provide a business update.
Ocugen will release a pre-market earnings announcement on the same day. Participants can join the call using the following details:
- U.S. callers: (800) 715-9871
- International callers: (646) 307-1963
- Conference ID: 9923172
A webcast will be available on the events section of the Ocugen investor site. A replay of the call and archived webcast will be accessible for approximately 45 days after the event.
Ocugen, a biotechnology company focused on gene and cell therapies, biologics, and vaccines, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will join a panel discussion on Ocular Drug Development on Tuesday, October 15, 2024, from 11 a.m. to noon EDT.
The panel will explore advancements in vision enhancement, disease modification, and vision restoration. Dr. Musunuri expressed excitement about introducing Ocugen's first-in-class modifier gene therapy platform to investors. The summit, presented by Maxim Group , will feature presentations and discussions with CEOs and key management from various healthcare companies, along with industry panels. The event is exclusive to M-Vest members and will take place from October 15 to October 17, 2024.
Ocugen, Inc. (NASDAQ: OCGN) announced that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial of OCU200, a recombinant fusion protein designed to treat diabetic macular edema (DME). OCU200 targets the integrin pathway and could potentially benefit all DME patients, including those unresponsive to current anti-VEGF therapies.
The trial is a multicenter, open-label, dose-ranging study with three cohorts in the dose-escalation portion and a fourth cohort combining OCU200 with anti-VEGF therapy. DME affects approximately 746,000 people in the United States. Ocugen plans to explore additional indications for OCU200, including diabetic retinopathy and wet age-related macular degeneration, which collectively impact nearly nine million Americans.
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced that its Chairman, CEO, and Co-founder, Dr. Shankar Musunuri, will present at the 2024 Cell & Gene Meeting on the Mesa on October 7, 2024, at 1:30 p.m. MST in Phoenix, AZ. The presentation will focus on Ocugen's first-in-class modifier gene therapy platform, including:
- OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa
- OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy
- OCU410ST Phase 1/2 GARDian clinical trial for Stargardt disease
OCU400 is on track for its 2026 BLA and MAA approval targets. The company's executive team will also conduct one-on-one meetings to discuss business and clinical development strategies. Virtual attendance options are available for the conference.
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event will take place on September 30-October 1, 2024 in New York.
Dr. Arun Upadhyay, Chief Scientific Officer and Head of Research & Development at Ocugen, will engage in an in-person fireside chat on September 30 at 10:30 a.m. ET. The session, moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, will focus on Ocugen's modifier gene therapy approach for retinal diseases and the progress of ongoing clinical trials for retinitis pigmentosa, geographic atrophy, and Stargardt disease.
The fireside chat will be accessible via a live video webcast on the Ocugen investor site. Additionally, Ocugen's executive team will conduct one-on-one meetings with investors to discuss the company's business and clinical development strategy.
Ocugen's Chairman, CEO, and Co-founder, Dr. Shankar Musunuri, is set to speak at a U.S.-India biotechnology cooperation workshop in New Delhi from September 9-11, 2024. The event, titled 'U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks,' is part of the U.S.-India Initiative on Critical and Emerging Technology.
Dr. Musunuri will participate in a panel discussion on 'Persistent Challenges: Right-Sizing Regulations and Setting Standards Beyond the Biomedical Sphere' on September 10. The workshop series, organized by the U.S. National Academies of Sciences, Engineering, and Medicine and the Indian National Science Academy, aims to identify opportunities for collaboration in biotechnology between the two countries.
Ocugen, a NASDAQ-listed biotechnology company (OCGN), focuses on gene and cell therapies, and vaccines. With its new site in Hyderabad, India, Ocugen is actively contributing to strengthening U.S.-India biotechnology cooperation.
Ocugen's Chief Scientific Officer, Dr. Arun Upadhyay, is set to participate in the 5th Annual Gene Therapy for Ophthalmic Disorders Summit in Boston from September 10-12, 2024. Dr. Upadhyay will moderate a workshop on regulatory pathways for ophthalmic gene therapies on September 10 and deliver a presentation on Ocugen's clinical program updates on September 12.
Ocugen (NASDAQ: OCGN) is a biotechnology company focused on gene and cell therapies, and vaccines. Dr. Upadhyay emphasized the potential of gene therapy in treating rare retinal diseases and widespread ophthalmic conditions. The conference provides an opportunity for Ocugen to showcase its modifier gene therapy platform and stay updated on industry advancements.
Ocugen Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will engage in a fireside chat on Monday, September 9, 2024, at 1:30 p.m. ET at the Lotte New York Palace Hotel.
The event provides an opportunity for Ocugen to showcase its recent corporate achievements and upcoming milestones. Additionally, the company's executive team will conduct one-on-one meetings with registered investors to discuss Ocugen's business and clinical development strategy, particularly focusing on its unique modifier gene therapy platform.
A live video webcast of the presentation will be available on Ocugen's investor site, with a replay archived for 90 days following the event.
FAQ
What is the current stock price of Ocugen (OCGN)?
What is the market cap of Ocugen (OCGN)?
